Meclocycline API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Meclocycline is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Meclocycline or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Meclocycline API 2013-58-3?

Description:
Here you will find a list of producers, manufacturers and distributors of Meclocycline. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Meclocycline 
Synonyms:
Meclociclina , Meclocyclinum  
Cas Number:
2013-58-3 
DrugBank number:
DB13092 
Unique Ingredient Identifier:
23Q8M2HE6S

General Description:

Meclocycline, identified by CAS number 2013-58-3, is a notable compound with significant therapeutic applications. Meclocycline is under investigation in clinical trial NCT00385515 (Efficacy of SNX-1012 in the Treatment of Oral Mucositis) .

Indications:

This drug is primarily indicated for: Currently under investigation for the topical treatment of ulcerative oral mucositis. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Meclocycline undergoes metabolic processing primarily in: Most tetracyclines are not metabolized. It is unlikely that meclocycline would be metabolized . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Meclocycline are crucial for its therapeutic efficacy: Estimated oral bioavailability of ~66% and tmax of 4h based on that of demeclocycline due to structural similarity . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Meclocycline is an important consideration for its dosing schedule: Half life estimated to be ~5.6h based on that of chlortetracycline due to structural similarity . This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Meclocycline exhibits a strong affinity for binding with plasma proteins: Estimated plasma protein binding of ~75-91% based on that of demeclocycline due to structural similarity . This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Meclocycline from the body primarily occurs through: Estimated urinary excretion of ~40% and fecal excretion of ~43% based on that of demeclocycline due to structural similarity . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Meclocycline is distributed throughout the body with a volume of distribution of: Estimated Vd of 121L based on that of demeclocycline due to structural similarity . This metric indicates how extensively the drug permeates into body tissues.

Pharmacodynamics:

Meclocycline exerts its therapeutic effects through: Tetracyclines such as meclocycline are broad spectrum bacteriostatic agents . Meclocyclin likely inhibits the growth of bacterial species present in the damaged oral mucosa, allowing the immune system to more easily eliminate infections. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Meclocycline functions by: As a tetracycline, meclocycline likely works by reversably associating with the 30s subint of the bacterial ribosome . A likely binding site for tetracyclines has been identified on protein S7 of this subunit. This association blocks the association of aminoacyl-tRNA with the ribosome, inhibiting protein synthesis. Ultimately this inhibits bacterial growth due to a lack of proteins necessary for reproduction. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Meclocycline belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups, classified under the direct parent group Tetracyclines. This compound is a part of the Organic compounds, falling under the Phenylpropanoids and polyketides superclass, and categorized within the Tetracyclines class, specifically within the None subclass.

Categories:

Meclocycline is categorized under the following therapeutic classes: Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Bacterial Agents, Anti-Infective Agents, Antiinfectives for Treatment of Acne, Dermatologicals, Naphthacenes, Tetracyclines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Meclocycline include:

  • Water Solubility: Soluble

Meclocycline is a type of Other substances


The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.

Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.

Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.

Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.

In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.